Obesity Management in Patients with Type 2 Diabetes and Depression/Anxiety Concerns

Introduction to Alternative Medications

The American College of Cardiology recommends semaglutide 2.4mg weekly as an alternative to tirzepatide for patients with type 2 diabetes and depression/anxiety concerns, offering superior weight loss and proven cardiovascular benefit 1

Semaglutide 2.4mg weekly achieves 14.9% total body weight loss at 68 weeks, with 64.9% of patients achieving ≥10% weight loss, and reduces HbA1c by approximately 1.48% from baseline 1
Semaglutide provides dual benefits of glycemic control and substantial weight loss in patients with type 2 diabetes, with a psychiatric adverse event rate similar to that of tirzepatide 1

Semaglutide reduces composite cardiovascular death, nonfatal MI, or nonfatal stroke by 20% (HR 0.80, 95% CI 0.72-0.90) in patients with established cardiovascular disease, a proven benefit unlike tirzepatide 1

Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2, and caution is advised in patients with a history of pancreatitis 1, 2

Liraglutide 3.0mg daily achieves 5.6% weight loss at 1 year and is FDA-approved for obesity management, although less potent than semaglutide 2
Naltrexone/bupropion achieves 4.2-5.2% weight loss at 1 year and may provide dual benefit of treating depression while promoting weight loss, but is contraindicated in severe depression and can exacerbate anxiety 2, 3, 4
Phentermine/topiramate ER achieves 8.6-9.3% weight loss at 1 year, but requires careful consideration due to potential side effects, including cognitive impairment and increased risk of orofacial clefts in pregnancy 2

Patients on semaglutide or liraglutide should be monitored every 4 weeks during titration and every 3 months after reaching maintenance dose for weight loss progress, blood pressure, and cardiovascular risk factors, as well as signs of pancreatitis and gallbladder disease 1, 2
Patients on naltrexone/bupropion should be monitored closely for worsening depression or suicidal ideation, and evaluated at 12 weeks for discontinuation if <5% weight loss is achieved 2
Patients on phentermine/topiramate should be monitored for cognitive impairment, acute angle-closure glaucoma, and electrolyte imbalances, and evaluated at 12 weeks for discontinuation if <3% weight loss is achieved on the recommended dose 2